Tweet IRVINE, CA, JenaValve Technology has raised $50 million in an equity financing led by Bain Capital Life Sciences.
The Company also announces the appointment of Andrew Hack, MD, PhD, Managing Director of Bain Capital, to the JenaValve Board of Directors.
JenaValve's focus on advancing a breakthrough technology with the ability to improve patient lives embodies the characteristics we seek at Bain Capital Life Sciences.
About Bain Capital Life SciencesBain Capital Life Sciences (www.baincapitallifesciences.com) pursues investments in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally.
About JenaValveJenaValve Technology, Inc., with locations in Irvine, Calif., Leeds, U.K. and Munich, Germany, develops and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from aortic valve disease. | To read full story, visit https://startuparound.com/read/1580938207.8387024/JenaValve-Technology-Closes-$50M-Financing?ref=audio_experience